Solid Tumors Clinical Trials in Omaha, Nebraska

4 studies are recruiting for solid tumors in Omaha, Nebraska right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

    A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Nebraska Medical Center, Omaha, Nebraska
    Locations
    22 in total
    Run by
    Incyte Corporation

    See if you can join NCT07195916 on ClinicalTrials.gov

  2. A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

    The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Omaha, Nebraska
    Locations
    25 in total
    Run by
    Arcus Biosciences, Inc.

    See if you can join NCT05536141 on ClinicalTrials.gov

  3. A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

    This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorec…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists, Omaha, Nebraska
    Locations
    100 in total
    Run by
    Mirati Therapeutics Inc.

    See if you can join NCT07415031 on ClinicalTrials.gov

  4. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

    The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E…

    Stage
    Phase 2
    Ages
    8 and older
    Site
    Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha, Nebraska
    Locations
    70 in total
    Run by
    Fore Biotherapeutics

    See if you can join NCT05503797 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.